FindTrial
Sign In

Carboplatin + Paclitaxel

DRUG5 trials

Sponsors

European Organisation for Research and Treatment of Cancer - EORTC, Presage Biosciences, Sun Yat-sen University, University College, London, Vanderbilt-Ingram Cancer Center

Conditions

Endometrial CancerEsophageal Squamous Cell CarcinomaHead and Neck Squamous Cell CarcinomaOvarian CancerPlatinum Sensitive Ovarian Cancer (PSOC)Salivary Gland CancerUterine Neoplasms

Early Phase 1

PBI-MST-01(NCT04541108) Substudy TAK-02: Intratumoral Microdosing of TAK-676 in HNSCC
CompletedNCT06062602
Presage BiosciencesHead and Neck Squamous Cell Carcinoma
Start: 2021-07-26End: 2022-11-15Updated: 2023-10-06

Phase 2

Androgen Deprivation Therapy in Advanced Salivary Gland Cancer
CompletedNCT01969578
European Organisation for Research and Treatment of Cancer - EORTCSalivary Gland Cancer
Start: 2015-09-24End: 2024-02-16Updated: 2024-11-05
Trastuzumab Rezetecan and Carboplatin ± Bevacizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-sensitive Recurrent Ovarian Cancer
Not yet recruitingNCT07776171
Sun Yat-sen UniversityOvarian Cancer, Platinum Sensitive Ovarian Cancer (PSOC)
Start: 2026-09-30End: 2030-05-30Target: 176Updated: 2026-08-20
PhII Study of Toripalimab Followed by Definitive CRT & Adjuvant Toripalimab in Locally Advanced ESCC
Not yet recruitingNCT07836049
Vanderbilt-Ingram Cancer CenterEsophageal Squamous Cell Carcinoma
Start: 2026-12-31End: 2031-12-31Target: 20Updated: 2026-09-23

Phase 3

Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features (RAINBO) - NSMP-ORANGE Trial: Comparing Radiotherapy With Oral Progestin Tablets vs. the Current Standard Care, Radiotherapy and Chemotherapy, in Patients With NSMP Endometrial Cancer
RecruitingNCT07831902
University College, LondonEndometrial Cancer, Uterine Neoplasms
Start: 2026-06-29End: 2034-12-01Target: 600Updated: 2026-09-21

Related Papers

Hope for salivary gland cancer (SGC): EORTC HNCG/UKCRN 1206 randomized phase II study to evaluate the efficacy and safety of chemotherapy (CT) vs androgen deprivation therapy (ADT) inpatients with recurrent and/or metastatic androgen receptor (AR) expressing SGC (NCT01969578).
Journal of Clinical Oncology2018-05-201 citations